Lineage Cell Therapeutics, Inc.

For the period ended Dec 31, 2025. Filed Mar 5, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 5, 2026

LCTX$1.08+5.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations

(IN THOUSANDS, EXCEPT PER SHARE DATA)

	Year Ended December 31,
	2025	2024
REVENUES:
Collaboration revenues	$13,609	$8,149
Royalties, license and other revenues	947	1,350
Total revenues	14,556	9,499
OPERATING EXPENSES:
Cost of royalties	146	334
Research and development	17,729	12,472
General and administrative	18,460	18,171
Loss on impairment of intangible asset (Note 6 and Note 13)	14,840	—
Total operating expenses	51,175	30,977
Loss from operations	(36,619)	(21,478)
OTHER INCOME (EXPENSES):
Interest income, net	1,691	1,715
Loss on marketable equity securities, net	(8)	(8)
Change in fair value of warrant liability	(35,727)	2,128
Foreign currency transaction gain (loss), net	2,148	(269)
Other income (expense), net	(132)	(670)
Total other income (expenses)	(32,028)	2,896
LOSS BEFORE INCOME TAXES	(68,647)	(18,582)
Income tax benefit	5,280	—
NET LOSS	(63,367)	(18,582)
Net (income) loss attributable to noncontrolling interest	(166)	(27)
NET LOSS ATTRIBUTABLE TO LINEAGE	$(63,533)	$(18,609)
Net loss per common share attributable to Lineage basic and diluted	$(0.28)	$(0.09)
Weighted-average common shares used to compute basic and diluted net loss per common share	230,116	200,193

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.